Vertex reports second-quarter sales beat and raises FY2026 guidance
Vertex Pharmaceuticals reported second-quarter earnings of $4.73 per share, in line with analyst consensus, and quarterly sales of $3.334 billion, above the $3.232 billion estimate, while raising FY2026 sales guidance.